use
multiplex
intern
control
monitor
sampl
extract
inhibit
revers
transcriptasepcr
rtpcr
becom
routin
clinic
molecular
virolog
test
provid
increas
confid
neg
patient
result
bustin
mueller
bustin
nolan
rna
intern
control
prefer
dna
intern
control
typic
use
pcr
fail
monitor
revers
transcript
reaction
endogen
exogen
rna
intern
control
coextract
coamplifi
viral
target
describ
previous
espi
et
al
niester
tong
et
al
endogen
control
usual
mrna
present
patient
sampl
encod
housekeep
gene
typic
express
rel
uniform
level
exogen
control
usual
introduc
sampl
prior
extract
possibl
intern
control
includ
uniform
copi
number
reaction
simpl
achiev
use
exogen
intern
control
strictli
regul
copi
number
difficult
endogen
rna
sinc
express
mrna
vari
significantli
sampl
even
housekeep
gene
use
commonli
huggett
et
al
two
gener
approach
design
exogen
intern
control
specif
advantag
di
trani
et
al
espi
et
al
hoorfar
et
al
pitcher
et
al
competit
intern
control
use
primer
viral
target
sequenc
alter
probe
bind
sequenc
control
close
mimic
amplif
target
sequenc
ie
similar
pcr
effici
potenti
compet
tar
correspond
author
tel
fax
email
address
stevenj
aruplabcom
j
stevenson
get
amplif
low
viral
load
decreas
assay
sensit
anoth
limit
normal
requir
differ
intern
control
assay
final
process
gener
competit
intern
control
may
complex
typic
clinic
microbiolog
laboratori
second
approach
noncompetit
intern
control
use
sequenc
entir
unrel
viral
target
often
either
anoth
rna
viru
rna
transcript
howev
transcript
suffer
disadvantag
vulner
degrad
problem
viral
particl
less
sensit
furthermor
amplif
noncompetit
intern
control
may
accur
reflect
target
amplif
nevertheless
approach
wide
adopt
sinc
mani
laboratori
benefit
outweigh
potenti
disadvantag
intern
control
target
quantit
ensur
appropri
copi
number
reaction
quantit
intern
control
commerci
vendor
excel
solut
laboratori
either
tool
requir
grow
quantit
viru
find
cost
effect
potenti
use
singl
intern
control
target
rtpcr
reaction
limit
number
differ
intern
control
design
necessari
univers
intern
control
ad
sampl
prior
extract
detect
singl
set
primer
probe
irrespect
viru
ultim
assay
furthermor
sequenc
constraint
dictat
design
new
ic
primer
probe
set
eg
interact
viral
target
ic
primer
new
design
still
target
univers
control
intern
control
target
describ
armor
rna
arna
asuragen
formerli
ambion
intern
control
spike
qiagen
avl
lysi
buffer
prior
sampl
extract
concentr
suffici
yield
copi
ic
per
l
extract
sampl
copi
per
l
rtpcr
reaction
lower
concentr
ic
also
test
assay
develop
see
true
sar
posit
clinic
sampl
highli
infecti
difficult
obtain
posit
sampl
studi
spike
inactiv
sar
viru
gener
provid
matthia
niedrig
robert
koch
institut
berlin
concentr
sar
stock
approxim
copiesml
sampl
spun
min
rpm
prior
extract
supernat
extract
use
qiaamp
viral
rna
mini
kit
spin
protocol
follow
modif
final
step
column
elut
l
molecular
grade
water
prewarm
c
prior
centrifug
column
incub
min
c
real
time
sar
test
base
taqman
assay
publish
drosten
et
al
employ
rtpcr
kit
invitrogen
use
dttp
kit
replac
qiagen
quantitect
kit
util
dutp
place
dttp
provid
increas
protect
amplicon
contamin
make
assay
better
suit
clinic
test
ten
microlit
extract
sampl
ad
l
master
mix
consist
l
qiagen
quantitect
probe
rtpcr
master
mix
dntp
utp
mgcl
mm
final
concentr
buffer
qiagen
hotstartaq
dna
polymeras
l
qiagen
quantitect
rt
mix
contain
rt
enzym
omniscript
sensiscript
revers
transcriptas
sar
primer
nm
intern
control
primer
nm
sar
taqman
probe
nm
intern
control
taqman
probe
nm
tabl
u
heatlabil
ung
roch
diagnost
appli
biosystem
program
follow
rt
protocol
min
c
min
c
follow
cycl
pcr
c
c
data
analysi
done
sd
softwar
appli
biosystem
initi
singleplex
test
arna
amplif
perform
describ
l
reaction
sar
primer
probe
heat
denatur
arna
done
c
min
noroviru
assay
describ
previous
w
armor
rna
product
asuragen
formerli
ambion
evalu
fulfil
need
commerci
avail
intern
control
coat
protein
gene
target
sinc
sequenc
includ
asuragen
arna
use
sequenc
genbank
taqman
primerprob
combin
amplif
detect
region
within
gene
design
primer
express
appli
biosystem
central
portion
gene
target
sequenc
near
end
may
alter
creation
arna
two
differ
arna
sar
test
design
coat
protein
sequenc
amplifi
target
data
shown
arna
chosen
target
accur
method
quantit
materi
avail
arup
roch
hcv
taqman
assay
multiplex
intern
control
affect
amplif
desir
target
sequenc
often
nonspecif
competit
reaction
need
consid
crucial
maintain
sensit
target
gene
must
balanc
need
minim
number
intern
control
amplif
failur
neg
sampl
high
rate
ic
failur
gener
unaccept
level
repeat
test
clinic
laboratori
initi
copi
intern
control
target
introduc
sar
reaction
heat
denatur
arna
ad
directli
assay
master
mix
concentr
intern
control
appar
effect
amplif
sar
target
observ
data
shown
furthermor
templat
control
ntc
reaction
rnase
free
water
display
amplif
target
indic
accept
concentr
ic
target
multiplex
assay
next
evalu
determin
would
perform
qiagen
extract
sampl
dilut
inactiv
sar
viru
water
well
number
ntc
extract
ic
ad
avl
lysi
buffer
copi
per
reaction
amplif
sar
target
satisfactori
effici
ic
fail
amplifi
ntc
reaction
order
achiev
detect
rate
ic
concentr
increas
approxim
copi
per
reaction
level
ic
detect
ntc
reaction
lastli
effici
ic
detect
measur
extract
respiratori
sampl
actual
patient
twentytwo
respiratori
sampl
nasal
swab
nasal
wash
bal
sputum
unknown
respiratori
sourc
presum
sar
neg
extract
ic
assay
sampl
neg
sar
assay
signific
number
ic
failur
observ
sampl
test
five
sampl
retest
duplic
ic
fail
amplifi
two
sampl
base
result
ic
concentr
increas
copi
per
reaction
eighteen
sar
neg
sampl
repeat
fail
amplifi
ic
concentr
indic
measur
inhibit
determin
effect
ic
concentr
sar
target
detect
cross
threshold
seri
sar
viru
dilut
span
three
log
compar
without
ic
signific
differ
observ
tabl
addit
seven
replic
sampl
near
limit
detect
test
approxim
three
copi
per
reaction
without
ic
amplif
sar
reaction
alon
replic
detect
compar
replic
multiplex
reaction
data
shown
conclud
minor
loss
sensit
accept
trade
benefit
provid
intern
control
sar
neg
sampl
describ
spike
inactiv
sar
viru
concentr
approxim
copiesreact
one
log
assay
limit
detect
sampl
detect
indic
inhibit
detect
undop
neg
sampl
insuffici
prevent
detect
sar
target
even
low
viral
load
longterm
stabil
anoth
desir
featur
univers
intern
control
base
previou
experi
rel
instabl
frozen
sar
arna
use
posit
assay
control
ic
arna
lyophil
sar
arna
dilut
water
aliquot
frozen
c
howev
cross
threshold
control
becam
progress
later
time
investig
observ
cross
threshold
sar
arna
dilu
tion
store
c
week
compar
gener
use
freshli
dilut
materi
period
test
cross
threshold
dilut
contain
copi
per
reaction
delay
approxim
c
decreas
detect
target
result
support
decis
lyophil
ic
arna
enhanc
stabil
time
arna
approach
intern
control
also
use
two
assay
offer
recent
arup
detect
noroviru
separ
assay
group
ii
furthermor
two
addit
real
time
assay
develop
util
strategi
one
enteroviru
wc
anoth
capabl
detect
flu
flu
b
rsv
multiplex
reaction
manuscript
prepar
assay
use
hcv
arna
intern
control
target
region
within
coat
protein
gene
differ
primer
probe
sequenc
design
chang
necessari
sar
assay
use
taqman
chemistri
other
list
hybrid
probe
assay
assay
arna
dilut
bsa
solut
lyophil
enhanc
longterm
stabil
ic
cross
threshold
neg
control
two
noroviru
assay
examin
evalu
stabil
arna
time
averag
cross
threshold
first
month
clinic
test
januari
februari
n
compar
observ
approxim
month
later
septemb
octob
n
signific
differ
detect
time
period
tabl
data
provid
clear
evid
arna
ic
stock
stabl
period
least
month
lyophil
practic
option
look
stabil
control
materi
longterm
storag
pcr
assay
becam
implement
wide
clinic
laboratori
need
intern
control
achiev
greater
appreci
qualiti
dna
control
materi
steadili
improv
howev
develop
reagent
rna
target
lag
behind
recent
year
arna
phage
packag
system
appli
commerci
assay
hiv
hcv
forman
valsamaki
addit
mani
laboratori
develop
assay
describ
util
arna
technolog
control
beld
et
al
bressler
nolt
eisler
et
al
obstacl
assay
rna
target
routin
clinic
test
develop
stabl
intern
control
materi
common
approach
problem
use
either
vitro
gener
rna
transcript
cultur
viral
particl
limit
use
cultur
phage
intern
control
describ
previous
dreier
et
al
dreier
et
al
commerci
avail
product
often
first
choic
clinic
laboratori
first
report
describ
target
sequenc
contain
within
arna
one
advantag
arna
approach
intern
control
use
transcript
resist
rnase
often
present
patient
sampl
nake
rna
transcript
highli
vulner
addit
arna
mimic
close
true
viral
particl
therefor
like
sensit
problem
viral
decapsul
would
nake
rna
transcript
besid
enhanc
stabil
arna
particl
noninfecti
reduc
potenti
risk
lab
worker
arna
also
nonrepl
reduc
risk
laboratori
contamin
rel
viabl
phage
sinc
product
avail
commerci
elimin
need
cultur
viru
therefor
approach
appropri
laboratori
lack
resourc
use
hcv
arna
describ
quantit
intern
control
materi
straightforward
measur
common
quantit
hcv
assay
perform
mani
clinic
laboratori
sinc
assay
typic
calibr
secondari
standard
indirectli
primari
standard
ic
quantit
potenti
determin
high
degre
accuraci
quantit
arna
use
determin
initi
number
copi
includ
per
reaction
also
use
tool
qualiti
control
store
aliquot
ic
assay
regular
basi
part
laboratori
qualiti
assur
program
ensur
materi
degrad
time
result
present
use
arna
ic
noroviru
assay
indic
materi
stabl
least
month
lyophil
final
use
commerci
product
instead
materi
gener
lab
obtain
patient
sourc
provid
wellcharacter
sequenc
less
like
contain
variat
develop
assay
multiplex
intern
control
requir
care
optim
use
low
intern
control
copi
number
minim
potenti
competit
effect
two
reaction
howev
demonstr
studi
ic
level
set
low
result
unaccept
level
ic
failur
sinc
sampl
neg
target
ic
must
repeat
signific
level
ic
failur
unaccept
due
associ
increas
cost
choic
manag
intern
control
complex
depend
larg
laboratori
need
resourc
laboratori
seek
greater
degre
assay
standard
retain
measur
flexibl
target
coat
protein
sequenc
contain
within
arna
particl
provid
excel
solut
mani
problem
associ
intern
control
rtpcr
assay
use
asuragen
hcv
arna
provid
addit
benefit
